Patents by Inventor Daniel B. DIX

Daniel B. DIX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
    Patent number: 11926670
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: March 12, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang
  • Devices and methods for overfilling drug containers
    Patent number: 11918785
    Abstract: Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: March 5, 2024
    Assignee: REGENERON PHARMACEUTICALS INC.
    Inventors: Daniel B. Dix, Douglas Kamen, Kenneth Graham
  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20230406959
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Citrate buffered VEGF antagonist formulations
    Patent number: 11806398
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 11673967
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: June 13, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • DEVICES AND METHODS FOR OVERFILLING DRUG CONTAINERS
    Publication number: 20230158237
    Abstract: Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.
    Type: Application
    Filed: January 10, 2023
    Publication date: May 25, 2023
    Applicant: Regeneron Pharmaceuticals Inc.
    Inventors: Daniel B. DIX, Douglas KAMEN, Kenneth GRAHAM
  • Devices and methods for overfilling drug containers
    Patent number: 11577025
    Abstract: Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: February 14, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Douglas Kamen, Kenneth Graham
  • Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
    Publication number: 20210403581
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: June 9, 2021
    Publication date: December 30, 2021
    Inventors: Daniel B. Dix, Xiaolin Tang
  • VEGF Antagonist Formulations
    Publication number: 20210393530
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210393778
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 6, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
    Patent number: 11098127
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • VEGF Antagonist Formulations
    Publication number: 20210252105
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 5, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210252147
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies
    Publication number: 20210230283
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 29, 2021
    Inventors: Daniel B. Dix, Kenneth S. Graham, Douglas Kamen, Scott M. Walsh
  • Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
    Patent number: 11059896
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition to an anti-hIL-4R antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: July 13, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Xiaolin Tang
  • VEGF Antagonist Formulations
    Publication number: 20210077624
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES
    Publication number: 20210054100
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: July 16, 2020
    Publication date: February 25, 2021
    Inventors: Scott M. WALSH, Daniel B. DIX
  • Formulations of VEG antagonist fusion proteins and method of manufacturing them
    Patent number: 10857231
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: December 8, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Stabilized formulations containing anti-PCSK9 antibodies
    Patent number: 10752701
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 25, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • DEVICES AND METHODS FOR OVERFILLING DRUG CONTAINERS
    Publication number: 20200155760
    Abstract: Disclosed herein are methods for overfilling primary packaging components, and drug products prepared according to those methods. The methods may include introducing a volume of a formulated drug substance into a primary packaging component having a nominal volume, where the volume of the formulated drug substance is greater than the nominal volume of the primary packaging component. In some cases, the primary packaging component may be a prefillable syringe.
    Type: Application
    Filed: June 29, 2017
    Publication date: May 21, 2020
    Applicant: Regeneron Pharmaceuticals Inc.
    Inventors: Daniel B. DIX, Douglas KAMEN, Kenneth GRAHAM